Featured Research

from universities, journals, and other organizations

Blood glucose measure appears to provide little benefit in predicting risk of CVD

Date:
March 25, 2014
Source:
The JAMA Network Journals
Summary:
Adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease (CVD).

In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease (CVD), adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.

Related Articles


Because higher glucose levels have been associated with higher CVD incidence, it has been proposed that information on blood sugar control might improve doctors' ability to predict who will develop CVD, according to background information in the article.

Emanuele Di Angelantonio, M.D., of the University of Cambridge, United Kingdom, and colleagues with the Emerging Risk Factors Collaboration, conducted an analysis of data available from 73 studies involving 294,998 participants to determine whether adding information on HbA1c levels to information about conventional cardiovascular risk factors is associated with improvements in the prediction of CVD risk. Predicted 10-year risk categories were classified as low (<5 percent), intermediate (5 percent to <7.5 percent), and high (≥ 7.5 percent).

Among the primary findings of the researchers, adding information on levels of HbA1c to conventional CVD risk factors was associated with only slight improvement in risk discrimination (how well a statistical model can separate individuals who do and do not go on to develop CVD). In addition, they found that adding information on HbA1c did not improve the accuracy of probability predictors for patients with and without CVD.

"Contrary to recommendations in some guidelines, the current analysis of individual-participant data in almost 300,000 people without known diabetes and CVD at baseline indicates that measurement of HbA1c is not associated with clinically meaningful improvement in assessment of CVD risk," the authors write.


Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Emanuele Di Angelantonio, Pei Gao, Hassan Khan, Adam S. Butterworth, David Wormser, Stephen Kaptoge, Sreenivasa Rao Kondapally Seshasai, Alex Thompson, Nadeem Sarwar, Peter Willeit, Paul M Ridker, Elizabeth L. M. Barr, Kay-Tee Khaw, Bruce M. Psaty, Hermann Brenner, Beverley Balkau, Jacqueline M. Dekker, Debbie A. Lawlor, Makoto Daimon, Johann Willeit, Inger Njølstad, Aulikki Nissinen, Eric J. Brunner, Lewis H. Kuller, Jackie F. Price, Johan Sundström, Matthew W. Knuiman, Edith J. M. Feskens, W. M. M. Verschuren, Nicholas Wald, Stephan J. L. Bakker, Peter H. Whincup, Ian Ford, Uri Goldbourt, Agustín Gómez-de-la-Cámara, John Gallacher, Leon A. Simons, Annika Rosengren, Susan E. Sutherland, Cecilia Björkelund, Dan G. Blazer, Sylvia Wassertheil-Smoller, Altan Onat, Alejandro Marín Ibañez, Edoardo Casiglia, J. Wouter Jukema, Lara M. Simpson, Simona Giampaoli, Børge G. Nordestgaard, Randi Selmer, Patrik Wennberg, Jussi Kauhanen, Jukka T. Salonen, Rachel Dankner, Elizabeth Barrett-Connor, Maryam Kavousi, Vilmundur Gudnason, Denis Evans, Robert B. Wallace, Mary Cushman, Ralph B. D’Agostino, Jason G. Umans, Yutaka Kiyohara, Hidaeki Nakagawa, Shinichi Sato, Richard F. Gillum, Aaron R. Folsom, Yvonne T. van der Schouw, Karel G. Moons, Simon J. Griffin, Naveed Sattar, Nicholas J. Wareham, Elizabeth Selvin, Simon G. Thompson, John Danesh. Glycated Hemoglobin Measurement and Prediction of Cardiovascular Disease. JAMA, 2014; 311 (12): 1225 DOI: 10.1001/jama.2014.1873

Cite This Page:

The JAMA Network Journals. "Blood glucose measure appears to provide little benefit in predicting risk of CVD." ScienceDaily. ScienceDaily, 25 March 2014. <www.sciencedaily.com/releases/2014/03/140325164437.htm>.
The JAMA Network Journals. (2014, March 25). Blood glucose measure appears to provide little benefit in predicting risk of CVD. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/03/140325164437.htm
The JAMA Network Journals. "Blood glucose measure appears to provide little benefit in predicting risk of CVD." ScienceDaily. www.sciencedaily.com/releases/2014/03/140325164437.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins